Publications by authors named "Marianna Bareschino"
Article Synopsis
- - The epidermal growth factor receptor (EGFR) is a key target for treating advanced non-small cell lung cancer (NSCLC), with drugs like erlotinib and gefitinib focusing on this receptor as reversible inhibitors.
- - Patients with EGFR mutations respond well to these treatments but typically experience disease progression within 10 to 14 months.
- - Newer irreversible EGFR tyrosine kinase inhibitors (TKIs) like afatinib and PF299804 are being explored as alternatives that may overcome resistance to earlier drugs, although their exact role in treatment is still being clarified.
New avenues for second-line treatment of metastatic non-small-cell lung cancer.
Expert Rev Anticancer Ther
January 2009
Platinum-based doublets are the standard first-line therapy for patients with advanced non-small-cell lung cancer, with approximately a third of patients obtaining an objective response with first-line chemotherapy and another 20-30% achieving temporary disease stabilization. However, all patients inevitably experience disease progression. Three agents are approved for treating patients who progress after one prior regimen: docetaxel, pemetrexed and erlotinib.
View Article and Find Full Text PDFCurrently, combinations of chemotherapy and radiotherapy are the standard treatment approach for locally advanced NSCLC patients. Concomitant chemo-radiotherapy, although associated with increased acute toxicity, has demonstrated to be the better strategy over sequential chemoradiotherapy, and it is to be considered a standard approach in patients with good performance status (0-1). However, the approach to locally advanced NSCLC and to chemo-radiotherapy regimens remains heterogeneous among oncologists, and clinical outcomes are yet disappointing.
View Article and Find Full Text PDF